Curanex Pharmaceuticals Inc Common Stock

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board